Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Aβ(1-42) injections in the rat

Brain Research

Volumn 954, Issue 1, 2002, Pages 1-10

  Richardson, R L ^a   Kim, E M ^a   Shephard, R A ^a   Gardiner, T ^b   Cleary, J ^c   O'Hare, E ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Aggregated amyloid; Alzheimer's disease; Ibuprofen; Inflammation; Operant behavior

Indexed keywords

AMYLOID BETA PROTEIN; IBUPROFEN; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BEHAVIOR DISORDER; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG WITHDRAWAL; HIPPOCAMPUS; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRAINING; TREATMENT OUTCOME;

EID: 0036827728     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03006-8     Document Type: Article

References (56)

1. Andersen K., Launer L.J., Ott A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. Neurology. 45:1995;1441-1445.
2. Araujo D.M., Cotman C.W. β-Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res. 569:1992;141-145.
3. Bauer J., Ganter U., Strauss S., Stadmüller G., Frommberger U., Bauer H., Volk B., Berger M. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res. Immunol. 143:1992;650-657.
4. Breitner J.C.S., Gau B.A., Welsh K.A., Plassman B.L., McDonald W.M., Helms M.J., Anthony J.C. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 44:1994;227-232.
5. Breteler M.M.B., Van Duijn C.M., Chandra V. Medical history and risk of Alzheimer's disease: a collaborative re-analysis of case-control studies. Int. J. Epidemiol. 20:(2):1991;S36-42.
6. Broe G.A., Henderson A.S., Creasey H. A case-control study of Alzheimer's disease in Australia. Neurology. 40:1990;1698-1707.
7. Canning D.R., McKeown R.J., DeWitt D.A., Perry G., Wujek J.R., Frederickson R.C., Silver J. β-Amyloid of Alzheimer's disease induces reactive gliosis that inhibits axonal outgrowth. Exp. Neurol. 124:1993;289-298.
8. Chase N.T., Foster N.L., Fedio P., Brooks R., Mansi L., Di Chiro G. Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Ann. Neurol. 15:1984;S170-S174.
9. Citron M., Oltersdorf T., Haas C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Leiberburg I., Selkoe D.J. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 360:1992;672-674.
10. Cleary J., Hittner J.M., Semotuk M., Mantyh P., O' Hare E. Beta-amyloid(1-40) effects on behavior and memory. Brain Res. 682:1995;69-74.
11. Cole G.M., Frautschy S.A. Animal models for Alzheimer's disease. Alzheimer Dis. Rev. 2:(2-10):1997;33-41.
12. Cummings B.J., Cotman C.W. Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet. 346:1995;1524-1528.
13. Dickson D.W., Lee S.C., Mattiace L.A., Yen S.H., Brosnan C. Microglia and cytokines in neurological disease, with special references to AIDS and Alzheimer's disease. Glia. 7:1993;75-83.
14. Eikelenboom P., Hack C.E., Rozemuller J.M., Stam F.C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch. B Cell Pathol. 56:1989;259-262.
15. Esler W.P., Stimson E.R., Ghilardi J.R., Felix A.M., Lu Y., Vinters H.V., Mantyh P.W., Maggio J.E. A-beta deposition inhibitor screen using synthetic amyloid. Nat. Biotech. 15:1997;258-263.
16. Ettinger R.H., Staddon J.E.R. Decreased feeding associated with acute hypoxia in rats. Physiol. Behav. 29:1982;455-458.
17. Ettinger R.H., Staddon J.E.R. Operant regulation of feeding: a static analysis. Behav. Neurosci. 97:1993;639-653.
18. Ettinger R.H., Thompson S., Staddon J.E.R. Cholecystokinin, diet palatability and feeding regulation in rats. Physiol. Behav. 36:1986;801-809.
19. Frautschy S.A., Baird A., Cole G.M. Effects of injected Alzheimer β-amyloid cores in rat brain. Proc. Natl. Acad. Sci. USA. 88:1991;8362-8366.
20. French L.R., Schuman L.M., Mortimer J.A., Hutton J.T., Boatman R.A., Christians B. A case-control study of dementia of the Alzheimer's type. Am. J. Epidemiol. 121:1985;414-421.
21. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagoplan S., Johnson-Wood K., Khan K., Lee M., Lelbowitz P., McConlogue L., Montoya-Zavala M., Mucke L., Paganlnl L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527.
22. Giovannelli L., Casamenti F., Scali C., Bartolini L., Pepeu G. Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into the rat nucleus basalis. Neuroscience. 66:(4):1995;781-792.
23. Glenner G.G., Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122:1984;1131-1135.
24. Goate A., Chartier-Harlin M., Mullan M., Brown J., Crawford F., Fidani L., Gluffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rossor M., Owen M., Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 349:1991;704-706.
25. Griffin W.T.S., Stanley L.C., Ling C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA. 86:1989;7611-7615.
26. Haga S., Akai K., Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol. 77:1989;569-575.
27. Hoke A., Canning D.R., Malemud C.J., Silver J. Regional differences in reactive gliosis induced by substrate-bound β-amyloid. Exp. Neurol. 130:1994;56-66.
28. Itagaki S., McGeer P.L., Akiyami H., Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease. J. Neuroimmunol. 24:1989;173-182.
29. Jarret J.T., Berger E.P., Lansbury P.T. Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 32:(18):1993;4693-4697.
30. Jenkinson M.L., Bliss M.R., Brain A.T., Scott D.L. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br. J. Rheumatol. 28:(1):1988;86-88.
31. Kowall N.W., Beal M.F., Busciglio J., Duffy L.K., Yankner B.A. An in vivo model for the neurodegenerative effects of β amyloid and protection by substance P. Proc. Natl. Acad. Sci. USA. 88:1991;7247-7251.
32. Kowall N.W., McKee A.C., Yankner B.A., Beal M.F. In vivo neurotoxicity of beta-amyloid [β(1-40)] and the β(25-35) fragment. Neurobiol. Aging. 13:1992;537-542.
33. Malouf A.T. Effect of beta amyloid peptides on neurons in hippocampal slice cultures. Neurobiol. Aging. 13:1992;543-551.
34. Mandybur T.I., Chuirazzi B.A. Astrocytes and the plaques of Alzheimer's disease. Neurology. 40:1990;635-639.
35. May P.C., Gitter B.D., Waters D.C., Simmons L.K., Becker G.W., Small J.S., Robinson P.M. Beta-amyloid peptide in vitro toxicity: lot to lot variability. Neurobiol. Aging. 13:1992;605-607.
36. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16:(4):1989;516-527.
37. McGeer P.L., Harada N., Kimura H., McGeer E.G., Schulzer M. Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dementia. 3:1992;146-149.
38. McGeer P.L., Kawamata T., Walker D.G., Akiyama H., Tooyama I., McGeer E.G. Microglia in degenerative neurological disease. Glia. 7:1993;84-92.
39. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21:1995;195-218.
40. McGeer P.L., McGeer E.G., Rogers J., Sibley J. Anti-inflammatory drugs and Alzheimer's disease. Lancet. 335:1990;1037.
41. McGeer P.L., Rogers J., McGeer E.G. Neuroimmune mechanisms in Alzheimer's disease pathogenesis. Alzheimer Dis. Assoc. Disord. 8:1994;149-158.
42. Mrak R.E., Sheng J.G., Griffin W.S.T. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum. Pathol. 26:1995;816-823.
43. Näslund J., Haroutunian V., Mohs R. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. J. Am. Med. Assoc. 283:2000;1571-1577.
44. (1-42). Brain Res. 815:(1):1999;1-10.
45. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., cotman C.W. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13:1993;1676-1687.
46. Pike C.J., Cummings B.J., Monzavi R., Cottman C.W. β-Amyloid induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer's disease. Neuroscience. 63:1994;517-531.
47. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. Aggregation-related toxicity of synthetic β-amyloid protein in hippocampal cultures. Eur. J. Pharmacol. 207:1991;367-368.
48. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P., Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
49. Selkoe D.J. Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53:1994;438-447.
50. Sheng G.K., Mrak R.E., Griffin W.S. Microglial interleukin-1 alpha expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution. Neuropathol. Appl. Neurobiol. 21:1995;290-301.
51. Sigurdsson E.M., Lee J.M., Dong X.W., Hejna M.J., Lorens S.A. Bilateral injections of amyloid-β 25-35 into the amygdala of young fischer rats: behavioral, neurochemical, and time-dependent histopathological effects. Neurobiol. Aging. 18:1997;591-608.
52. Sigurdsson E.M., Lorens S.A., Hejna M.J., Dong X.W., Lee J.M. Local and distant histopathological effects of unilateral amyloid-β 25-35 injections into the amygdala of young F344 rats. Neurobiol. Aging. 17:1996;893-901.
53. Vane J.R. Inhibitor of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231:1971;232-235.
54. Webster S., Lue L.-F., Brachova L., Tenner A.J., McGeer P.L., Terai K., Walker D.G., Bradt B., Cooper N.R., Rogers J. Molecular and cellular characterization of the membrane attack complex C5b-9, in Alzheimer's disease. Neurobiol. Aging. 18:1997;415-421.
55. Weldon D.T., O'Hare E., Kuskowski M.A., Cleary J., Mach J.R. Alternating lever cyclic-ratio schedule analysis of the effects of atropine sulfate. Phramacol. Biochem. Behav. 54:1995;753-757.
56. Weldon D.T., Rogers S.D., Ghilardi J.R., Finke M.P., Cleary J.P., O'Hare E., Esler W.P., Maggio J.E., Mantyh P.W. Fibrillar β-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J. Neurosci. 18:(6):1998;2161-2173.